NSCLC Treatment - Recurrent or Refractory Disease
	Second-line Treatment
	Additional Treatment Options

Second-line Treatment

Second-line Weekly Paclitaxel in Patients with Inoperable NSCLC Who Fail Combination Chemotherapy With Cisplatin (PubMed)
Phase II study published in the August issue of Lung Cancer that found second-line treatment with single-agent paclitaxel is well-tolerated, active and associated with long survivals in inoperable NSCLC patients whose disease does not respond or recurs following standard front-line platinum-based chemotherapy. [8/04]

Pemetrexed May Be Equivalent to Docetaxel in Treating Recurrent NSCLC (People Living With Cancer)
Report on a study presented at the 2003 ASCO annual meeting that evaluated the effectiveness of docetaxel (Taxotere) and pemetrexed (Alimta). Researchers found that pemetrexed is as effective as docetaxel in treating patients with NSCLC that has recurred following treatment. [5/03]

Second-line Treatment - Recent MEDLINE Abstracts (PubMed)

Additional Treatment Options

Third-line Treatment - Recent MEDLINE Abstracts (PubMed)

"Salvage" Treatment - Recent MEDLINE Abstracts (PubMed)